Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Down 27.1% in November

Capricor Therapeutics Inc (NASDAQ:CAPR) saw a large decrease in short interest in November. As of November 15th, there was short interest totalling 3,850,000 shares, a decrease of 27.1% from the October 31st total of 5,280,000 shares. Based on an average trading volume of 3,160,000 shares, the days-to-cover ratio is currently 1.2 days.

Insider Transactions at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the firm’s stock in a transaction dated Friday, September 20th. The shares were bought at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the acquisition, the insider now owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. This trade represents a 65.21 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 12.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CAPR. Vanguard Group Inc. boosted its stake in shares of Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after purchasing an additional 200,499 shares during the period. Renaissance Technologies LLC boosted its position in Capricor Therapeutics by 158.7% in the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after purchasing an additional 84,350 shares during the last quarter. Marshall Wace LLP bought a new stake in Capricor Therapeutics during the 2nd quarter valued at approximately $426,000. Rhumbline Advisers bought a new stake in Capricor Therapeutics during the 2nd quarter valued at approximately $147,000. Finally, Bank of New York Mellon Corp raised its stake in Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares during the period. 21.68% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on CAPR. Cantor Fitzgerald boosted their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Piper Sandler initiated coverage on shares of Capricor Therapeutics in a report on Monday, October 21st. They set an “overweight” rating and a $35.00 target price for the company. Maxim Group increased their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Oppenheimer reaffirmed an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a research report on Thursday, November 14th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Trading Down 0.2 %

Capricor Therapeutics stock traded down $0.03 during trading hours on Friday, reaching $19.01. 571,850 shares of the stock were exchanged, compared to its average volume of 1,108,092. The stock has a 50 day moving average of $18.03 and a two-hundred day moving average of $9.41. Capricor Therapeutics has a twelve month low of $2.90 and a twelve month high of $23.40.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.